REG - GlaxoSmithKline PLC - Director/PDMR Shareholding
RNS Number : 7662PGlaxoSmithKline PLC19 February 2021GlaxoSmithKline plc (the 'Company')
Transaction notification
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Mr J Ford
b)
Position/status
SVP & General Counsel
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
American Depositary Shares ('ADSs')
ISIN: US37733W1053
b)
Nature of the transaction
Following the vesting on 16 February 2021 of an award made on 6 September 2018 under the GlaxoSmithKline Deferred Investment Award programme in lieu of a Share Value Plan award, Mr Ford will receive a cash payment of $225,308 less applicable tax withholding in respect of 6,320 notional American Depositary Shares.
c)
Price(s) and volume(s)
Price(s)
Volume(s)
$35.6500
6,320
d)
Aggregated information
N/A (single transaction)
Aggregated volume Price
e)
Date of the transaction
2021-02-17
f)
Place of the transaction
N/A
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Ms D Waterhouse
b)
Position/status
CEO of ViiV Healthcare
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
b)
Nature of the transaction
Following the vesting on 16 February 2021 of an award made on 16 February 2015 under the GlaxoSmithKline Deferred Investment Award programme in lieu of a Share Value Plan award, Ms Waterhouse will receive a cash payment of £194,803.33 less applicable tax withholding in respect of 15,302.697 notional Ordinary Shares.
c)
Price(s) and volume(s)
Price(s)
Volume(s)
£12.7300
.
15,302.697
d)
Aggregated information
N/A (single transaction)
Aggregated volume Price
e)
Date of the transaction
2021-02-17
f)
Place of the transaction
N/A
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.ENDDSHLKLFFFLLLBBK
Recent news on GSK
See all newsREG - GSK PLC - Director/PDMR Shareholding
AnnouncementREG - GSK PLC - GSK submits Arexvy for adults 18+ with EMA
AnnouncementREG - GSK PLC - Transaction in Own Shares
AnnouncementREG-GSK Plc: Director/PDMR Shareholding
AnnouncementREG - GSK PLC - Transaction in Own Shares
Announcement